Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1223-1229

  Nel, I ^a   Gauler, T C ^b   Eberhardt, W E ^b   Nickel, A C ^a   Schuler, M ^b   Thomale, J ^c   Hoffmann, A C ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Pt (GpG) DNA adducts; circulating tumour cells; pre therapeutic; ex vivo; non small cell lung cancer; platinum based chemotherapy

Indexed keywords

CD15 ANTIGEN; CD45 ANTIGEN; CELL NUCLEUS DNA; CISPLATIN; CYTOKERATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL ISOLATION; CELL LEVEL; CIRCULATING TUMOR CELL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DNA REPAIR; DRUG DNA INTERACTION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PT GPG ADDUCT;

AGED; ANTIGENS, CD15; ANTIGENS, CD45; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DINUCLEOSIDE PHOSPHATES; DNA ADDUCTS; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PLATINUM; TUMOR CELLS, CULTURED;

EID: 84883742656     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.419     Document Type: Conference Paper

References (22)

1. Bracker TU, Giebel B, Spanholtz J, Sorg UR, Klein-Hitpass L, Moritz T, Thomale J (2006) Stringent regulation of DNA repair during human hematopoietic differentiation: a gene expression and functional analysis. Stem Cells 24(3): 722-730. (Pubitemid 44464777)
2. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19): 2747-2754. (Pubitemid 47123183)
3. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12): 1101-1110.
4. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, De Vere White RW, Turteltaub KW, Pan CX (2011) A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance Int J Cancer 129(6): 1425-1434.
5. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P (2009) A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 15(16): 5191-5198.
6. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, Hoelscher AH, Danenberg KD, Prenzel KL, Danenberg PV (2008) High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10(7): 674-679. (Pubitemid 351883883)
7. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, Hartmann A (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8): 628-636.
8. Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6(10): e25164.
9. Joly E, Hudrisier D (2003) What is trogocytosis and what is its purpose? Nat Immunol 4(9): 815-816.
10. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8): 573-584. (Pubitemid 47106628)
11. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27): 3345-3352.
12. Liedert B, Pluim D, Schellens J, Thomale J (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34(6): e47.
13. Nel I, Ertlel JM, Baba HA, Weber F, Sitek B, Stephan C, Meyer H, Schlaak JF, Hoffmann AC (2012) A novel method for the detection of different subgroups of circulating tumor cells in patients with hepatocellular carcinoma. Hepatology 56: 457A-457A.
14. Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, Andre F, Brambilla E, Soria JC (2013) PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer 80(2): 216-222.
15. Olaussen KA, Andre F, Soria JC (2012) DNA repair capacity in circulating lymphocytes and influence on platinum effect in tumor cells. J Clin Oncol 30(13): 1567-1568, author reply 1568-9.
16. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24(8): 837-852.
17. Printz C (2010) BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 116(14): 3307-3308.
18. Sobin LH (2003) TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 21(1): 3-7. (Pubitemid 37127467)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216. (Pubitemid 30099779)
20. Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, Spitz MR, Wei Q (2011a) DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 29(31): 4121-4128.
21. Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, Wani AA (2011b) Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer 10: 24-36.
22. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3): 373-382.